top of page

Real-time surgical
leak detection technology

The first and only real-time, quantifiable leak detection test built on an advanced constant flow insufflator 

Leak Detection Screen April 2025.png

About Qaelon

Qaelon is dedicated to reducing the devastating impact of surgical leaks on patients while empowering surgeons with the ability to intervene before the patient leaves the operating room.

 

Our mission is to provide real-time, reliable detection of surgical leaks, enhancing patient safety, and surgical outcomes.

Our Technology

Qaelon's breakthrough technology utilizes digital sensors and proprietary software, along with advanced data algorithms, to accurately detect tiny leaks (<1mm) that are often missed by the "air bubble" test. Our patented solution replaces error-prone analog visual tests, setting a new standard in surgical leak detection.

Surgeons in Operation Room
About Qaelon

Surgical leaks are the most dreaded complication.

With devastating patient outcomes.

5 -19%

Leak Rate

18%

Mortality Rate for early leaks

+86%

Re-operation Rate

And staggering treatment costs.

$1.1 Billion

Annual Treatment Cost 

(US Only)

Cost Per Patient

$ 35,000

$ 41,000

$121,000

Colon

Stomach

Esophagus 

Qaelon’s innovative solution creates a new standard of care for surgical leak detection and insufflation.

Our Technology

Collaborators

Our Partnerships

Qaelon Medical is collaborating with Caresyntax to leverage their surgical intelligence platform to capture real world evidence that proves the accuracy of our system, and quantifies the impact on leak rates and total healthcare costs.

 

We are also partnering with leading medtech companies to integrate their device data into our RWE algorithms to better predict the risk factors of surgical leaks.  

caresyntx.png
revmedica.png
nvidia.png

News & Events

Contact us

Inquiry

Address

Qaelon Medical, IHU, 1 Place de l’Hôpital

67091 Strasbourg, France
 

Email

yee-ying.douchamps@qaelonmedical.com

  • LinkedIn

Note: Qaelon Medical products are currently under development, have not been cleared by the FDA, and are not yet available for commercial sale in the United States or Europe.

Qaelon Medical, IHU, 1 Place de l’Hôpital

67091 Strasbourg, France

Email: yee-ying.douchamps@qaelonmedical.com

  • LinkedIn

© 2025 Qaelon Medical

bottom of page